Raymond J. Hohl - Publications

Molecular & Cell Biology University of Iowa, Iowa City, IA 
Molecular Biology, Biochemistry

116 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Weissenrieder JS, Neighbors JD, Mailman RB, Hohl RJ. Cancer and the dopamine D2 receptor: a pharmacological perspective. The Journal of Pharmacology and Experimental Therapeutics. PMID 31000578 DOI: 10.1124/jpet.119.256818  0.84
2019 Kokolus KM, Haley JS, Koubek EJ, Gowda R, Dinavahi SS, Sharma A, Claxton DF, Helm KF, Drabick JJ, Robertson GP, Neighbors JD, Hohl RJ, Schell TD. Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. Oncoimmunology. 8: e1539614. PMID 30713799 DOI: 10.1080/2162402X.2018.1539614  0.84
2018 Koubek EJ, Weissenrieder JS, Neighbors JD, Hohl RJ. Schweinfurthins: Lipid Modulators with Promising Anticancer Activity. Lipids. PMID 30334267 DOI: 10.1002/lipd.12088  0.84
2018 Weissenrieder JS, Reilly JE, Neighbors JD, Hohl RJ. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models. The Prostate. PMID 30106164 DOI: 10.1002/pros.23707  0.84
2016 Reilly JE, Neighbors JD, Hohl RJ. Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis. Cancer Biology & Therapy. 0. PMID 27624889 DOI: 10.1080/15384047.2016.1219817  0.84
2015 Kuder CH, Weivoda MM, Zhang Y, Zhu J, Neighbors JD, Wiemer DF, Hohl RJ. 3-Deoxyschweinfurthin B Lowers Cholesterol Levels by Decreasing Synthesis and Increasing Export in Cultured Cancer Cell Lines. Lipids. PMID 26494560 DOI: 10.1007/s11745-015-4083-z  1
2015 Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clinical & Experimental Metastasis. 32: 555-66. PMID 26070429 DOI: 10.1007/s10585-015-9727-0  1
2015 Sheehy RM, Kuder CH, Bachman Z, Hohl RJ. Calcium and P-glycoprotein independent synergism between schweinfurthins and verapamil. Cancer Biology & Therapy. 16: 1259-68. PMID 26046259 DOI: 10.1080/15384047.2015.1056420  0.92
2015 Reilly JE, Zhou X, Tong H, Kuder CH, Wiemer DF, Hohl RJ. In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors. Biochemical Pharmacology. 96: 83-92. PMID 25952057 DOI: 10.1016/j.bcp.2015.04.009  1
2015 Ferguson NN, Thomas CP, Hohl RJ, Syrbu SI, Stone MS, Wanat KA. Primary Cutaneous Polymorphic EBV-Associated Posttransplant Lymphoproliferative Disorder After a Renal Transplant and Review of the Literature. The American Journal of Dermatopathology. PMID 25747810 DOI: 10.1097/DAD.0000000000000272  1
2015 Holstein SA, Bigelow JC, Olson RD, Vestal RE, Walsh GM, Hohl RJ. Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors. Investigational New Drugs. 33: 594-602. PMID 25698442 DOI: 10.1007/s10637-015-0220-z  0.36
2015 Hohl RJ. Oncology trial design: More accurately and efficiently advancing the field Clinical Pharmacology and Therapeutics. 97: 430-432. PMID 25684240 DOI: 10.1002/cpt.94  1
2015 Holstein SA, Bigelow JC, Olson RD, Vestal RE, Walsh GM, Hohl RJ. Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors Investigational New Drugs. DOI: 10.1007/s10637-015-0220-z  1
2014 Hohl RJ. Drug development (and academic medicine): charting the course forward Clinical Pharmacology and Therapeutics. 96: 519-522. PMID 25336261 DOI: 10.1038/clpt.2014.171  1
2014 Zhou X, Reilly JE, Loerch KA, Hohl RJ, Wiemer DF. Synthesis of isoprenoid bisphosphonate ethers through C-P bond formations: Potential inhibitors of geranylgeranyl diphosphate synthase. Beilstein Journal of Organic Chemistry. 10: 1645-50. PMID 25161722 DOI: 10.3762/bjoc.10.171  1
2013 Hohl RJ. Personalized medicine: through the looking glass of functional imaging. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4024-6. PMID 23785049 DOI: 10.1158/1078-0432.CCR-13-1129  1
2013 Tong H, Kuder CH, Wasko BM, Hohl RJ. Quantitative determination of isopentenyl diphosphate in cultured mammalian cells. Analytical Biochemistry. 433: 36-42. PMID 23000003 DOI: 10.1016/j.ab.2012.09.001  1
2012 Holstein SA, Hohl RJ. Is there a future for prenyltransferase inhibitors in cancer therapy? Current Opinion in Pharmacology. 12: 704-9. PMID 22817869 DOI: 10.1016/j.coph.2012.06.013  1
2012 Kuder CH, Sheehy RM, Neighbors JD, Wiemer DF, Hohl RJ. Functional evaluation of a fluorescent schweinfurthin: mechanism of cytotoxicity and intracellular quantification. Molecular Pharmacology. 82: 9-16. PMID 22461663 DOI: 10.1124/mol.111.077107  1
2012 Holstein SA, Hohl RJ. Therapeutic additions and possible deletions in oncology in 2011 Clinical Pharmacology and Therapeutics. 91: 15-17. PMID 22179625 DOI: 10.1038/clpt.2011.288  1
2012 Weivoda MM, Hohl RJ. Geranylgeranyl pyrophosphate stimulates PPARγ expression and adipogenesis through the inhibition of osteoblast differentiation. Bone. 50: 467-76. PMID 22019459 DOI: 10.1016/j.bone.2011.09.056  1
2012 Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Pérez I, Nieto A, Tercero JC, Alfaro V, Tamborini E, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 771-6. PMID 21642514 DOI: 10.1093/annonc/mdr265  1
2011 Wiemer AJ, Wiemer DF, Hohl RJ. Geranylgeranyl diphosphate synthase: an emerging therapeutic target. Clinical Pharmacology and Therapeutics. 90: 804-12. PMID 22048229 DOI: 10.1038/clpt.2011.215  1
2011 Wasko BM, Smits JP, Shull LW, Wiemer DF, Hohl RJ. A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro. Journal of Lipid Research. 52: 1957-64. PMID 21903868 DOI: 10.1194/jlr.M016089  1
2011 Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A. Clinical pharmacology as a foundation for translational science Clinical Pharmacology and Therapeutics. 90: 10-13. PMID 21691266 DOI: 10.1038/clpt.2011.80  1
2011 Holstein SA, Kuder CH, Tong H, Hohl RJ. Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis. Lipids. 46: 907-21. PMID 21633866 DOI: 10.1007/s11745-011-3572-y  1
2011 Weivoda MM, Hohl RJ. Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation. Endocrinology. 152: 3113-22. PMID 21586555 DOI: 10.1210/en.2011-0016  1
2011 Weivoda MM, Hohl RJ. The effects of direct inhibition of geranylgeranyl pyrophosphate synthase on osteoblast differentiation. Journal of Cellular Biochemistry. 112: 1506-13. PMID 21503955 DOI: 10.1002/jcb.23087  1
2011 Wasko BM, Dudakovic A, Hohl RJ. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. The Journal of Pharmacology and Experimental Therapeutics. 337: 540-6. PMID 21335425 DOI: 10.1124/jpet.110.175521  1
2011 Holstein SA, Hohl RJ. Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leukemia Research. 35: 551-9. PMID 20828814 DOI: 10.1016/j.leukres.2010.08.008  1
2011 Dudakovic A, Tong H, Hohl RJ. Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration. Investigational New Drugs. 29: 912-20. PMID 20480384 DOI: 10.1007/s10637-010-9446-y  1
2011 Holstein SA, Hohl RJ. Inhibition of Farnesyl and Geranylgeranyl Diphosphate Synthases Enzymes. 30: 301-319. DOI: 10.1016/B978-0-12-415922-8.00013-6  1
2010 Ulrich NC, Kuder CH, Hohl RJ, Wiemer DF. Biologically active biotin derivatives of schweinfurthin F. Bioorganic & Medicinal Chemistry Letters. 20: 6716-20. PMID 20869871 DOI: 10.1016/j.bmcl.2010.08.143  1
2010 Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF. Synthesis and biological evaluation of a series of aromatic bisphosphonates. Bioorganic & Medicinal Chemistry. 18: 7212-20. PMID 20832326 DOI: 10.1016/j.bmc.2010.08.036  1
2010 Topczewski JJ, Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF. Fluorescent schweinfurthin B and F analogs with anti-proliferative activity. Bioorganic & Medicinal Chemistry. 18: 6734-41. PMID 20724169 DOI: 10.1016/j.bmc.2010.07.056  1
2010 Ulrich NC, Kodet JG, Mente NR, Kuder CH, Beutler JA, Hohl RJ, Wiemer DF. Structural analogues of schweinfurthin F: probing the steric, electronic, and hydrophobic properties of the D-ring substructure. Bioorganic & Medicinal Chemistry. 18: 1676-83. PMID 20116262 DOI: 10.1016/j.bmc.2009.12.063  1
2010 Holstein SA, Tong H, Hohl RJ. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells. Leukemia Research. 34: 344-51. PMID 19646757 DOI: 10.1016/j.leukres.2009.06.035  1
2010 Phillips PS, Verity MA, Schick BA, Vladutiu GD, Laaksonen R, Oresic M, Hohl RJ, Ciaraldi TP, Sukhatme VP, Lecker SH, Cote HCF, Powell H, Davidson W, Wolfson T. Survey of muscle characteristics after statin-induced rhabdomyolysis Clinical Lipidology. 5: 17-27. DOI: 10.2217/clp.09.83  1
2009 Holstein SA, Tong H, Kuder CH, Hohl RJ. Quantitative determination of geranyl diphosphate levels in cultured human cells. Lipids. 44: 1055-62. PMID 19856009 DOI: 10.1007/s11745-009-3355-x  1
2009 Holstein SA, Hohl RJ. Vascular medicine: A look forward Clinical Pharmacology and Therapeutics. 86: 117-119. PMID 19621001 DOI: 10.1038/clpt.2009.125  1
2009 Wiemer AJ, Hohl RJ, Wiemer DF. The intermediate enzymes of isoprenoid metabolism as anticancer targets. Anti-Cancer Agents in Medicinal Chemistry. 9: 526-42. PMID 19519294  1
2009 Kuder CH, Neighbors JD, Hohl RJ, Wiemer DF. Synthesis and biological activity of a fluorescent schweinfurthin analogue. Bioorganic & Medicinal Chemistry. 17: 4718-23. PMID 19464190 DOI: 10.1016/j.bmc.2009.04.071  1
2009 Chanan-Khan AA, Niesvizky R, Hohl RJ, Zimmerman TM, Christiansen NP, Schiller GJ, Callander N, Lister J, Oken M, Jagannath S. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leukemia & Lymphoma. 50: 559-65. PMID 19373653 DOI: 10.1080/10428190902748971  1
2009 Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, ... Hohl RJ, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1800-5. PMID 19255312 DOI: 10.1200/JCO.2008.20.0931  1
2009 Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leukemia Research. 33: 344-7. PMID 18835038 DOI: 10.1016/j.leukres.2008.07.029  1
2008 McLennan G, Clarke L, Hohl RJ. Imaging as a biomarker for therapy response: Cancer as a prototype for the creation of research resources Clinical Pharmacology and Therapeutics. 84: 433-436. PMID 18802422 DOI: 10.1038/clpt.2008.171  1
2008 Tong H, Wiemer AJ, Neighbors JD, Hohl RJ. Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue. Analytical Biochemistry. 378: 138-43. PMID 18457649 DOI: 10.1016/j.ab.2008.04.021  1
2008 Wiemer AJ, Yu JS, Shull LW, Barney RJ, Wasko BM, Lamb KM, Hohl RJ, Wiemer DF. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Bioorganic & Medicinal Chemistry. 16: 3652-60. PMID 18308574 DOI: 10.1016/j.bmc.2008.02.016  1
2008 Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207 Annals of Oncology. 19: 946-950. PMID 18272914 DOI: 10.1093/annonc/mdm600  1
2008 Dudakovic A, Wiemer AJ, Lamb KM, Vonnahme LA, Dietz SE, Hohl RJ. Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes. The Journal of Pharmacology and Experimental Therapeutics. 324: 1028-36. PMID 18083912 DOI: 10.1124/jpet.107.132217  1
2008 Hamadmad SN, Hohl RJ. Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism. The Journal of Pharmacology and Experimental Therapeutics. 324: 1227-33. PMID 18079357 DOI: 10.1124/jpet.107.129643  1
2008 Wiemer AJ, Yu JS, Lamb KM, Hohl RJ, Wiemer DF. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorganic & Medicinal Chemistry. 16: 390-9. PMID 17905588 DOI: 10.1016/j.bmc.2007.09.029  1
2007 Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ, Lichtman SM, Ratain MJ. Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3055-60. PMID 17634483 DOI: 10.1200/JCO.2007.11.6210  1
2007 Hamadmad SN, Hohl RJ. Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation. Biochemical Pharmacology. 74: 590-600. PMID 17586475 DOI: 10.1016/j.bcp.2007.04.028  1
2007 Hohl RJ. Clinical pharmacology: Bridging discovery and practice Clinical Pharmacology and Therapeutics. 81: 783-785. PMID 17505487 DOI: 10.1038/sj.clpt.6100225  1
2007 Xing D, Murry DJ, Schmidt MS, Hohl RJ, Martins JB. Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity. Heart Rhythm : the Official Journal of the Heart Rhythm Society. 4: 629-37. PMID 17467633 DOI: 10.1016/j.hrthm.2006.12.051  1
2007 Widness JA, Schmidt RL, Hohl RJ, Goldman FD, Al-Huniti NH, Freise KJ, Veng-Pedersen P. Change in erythropoietin pharmacokinetics following hematopoietic transplantation Clinical Pharmacology and Therapeutics. 81: 873-879. PMID 17429351 DOI: 10.1038/sj.clpt.6100165  1
2007 Maalouf MA, Wiemer AJ, Kuder CH, Hohl RJ, Wiemer DF. Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation. Bioorganic & Medicinal Chemistry. 15: 1959-66. PMID 17254791 DOI: 10.1016/j.bmc.2007.01.002  1
2007 Mente NR, Wiemer AJ, Neighbors JD, Beutler JA, Hohl RJ, Wiemer DF. Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series. Bioorganic & Medicinal Chemistry Letters. 17: 911-5. PMID 17236766 DOI: 10.1016/j.bmcl.2006.11.096  1
2007 Wiemer AJ, Tong H, Swanson KM, Hohl RJ. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochemical and Biophysical Research Communications. 353: 921-5. PMID 17208200 DOI: 10.1016/j.bbrc.2006.12.094  1
2006 Shull LW, Wiemer AJ, Hohl RJ, Wiemer DF. Synthesis and biological activity of isoprenoid bisphosphonates. Bioorganic & Medicinal Chemistry. 14: 4130-6. PMID 16517172 DOI: 10.1016/j.bmc.2006.02.010  1
2006 Swanson KM, Hohl RJ. Anti-cancer therapy: targeting the mevalonate pathway. Current Cancer Drug Targets. 6: 15-37. PMID 16475974 DOI: 10.2174/156800906775471743  1
2006 Hamadmad SN, Henry MK, Hohl RJ. Erythropoietin receptor signal transduction requires protein geranylgeranylation. The Journal of Pharmacology and Experimental Therapeutics. 316: 403-9. PMID 16203826 DOI: 10.1124/jpet.105.092510  1
2006 Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemotherapy and Pharmacology. 57: 155-64. PMID 16133537 DOI: 10.1007/s00280-005-0013-8  1
2005 Murthy S, Tong H, Hohl RJ. Regulation of fatty acid synthesis by farnesyl pyrophosphate. The Journal of Biological Chemistry. 280: 41793-804. PMID 16221687 DOI: 10.1074/jbc.M504101200  1
2005 Lewis KA, Holstein SA, Hohl RJ. Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. Leukemia Research. 29: 527-33. PMID 15755505 DOI: 10.1016/j.leukres.2004.10.007  1
2005 Tong H, Holstein SA, Hohl RJ. Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells. Analytical Biochemistry. 336: 51-9. PMID 15582558 DOI: 10.1016/j.ab.2004.09.024  1
2004 Kim M, Kleckley TS, Wiemer AJ, Holstein SA, Hohl RJ, Wiemer DF. Synthesis and activity of fluorescent isoprenoid pyrophosphate analogues. The Journal of Organic Chemistry. 69: 8186-93. PMID 15549786 DOI: 10.1021/jo049101w  1
2004 Holstein SA, Hohl RJ. Isoprenoids: remarkable diversity of form and function. Lipids. 39: 293-309. PMID 15357017 DOI: 10.1007/s11745-004-1233-3  1
2004 Henry MK, Nimbalkar D, Hohl RJ, Quelle FW. Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells. Experimental Cell Research. 299: 257-66. PMID 15302592 DOI: 10.1016/j.yexcr.2004.06.003  1
2004 Burns CP, Halabi S, Clamon G, Kaplan E, Hohl RJ, Atkins JN, Schwartz MA, Wagner BA, Paskett E. Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia. Cancer. 101: 370-8. PMID 15241836 DOI: 10.1002/cncr.20362  1
2004 Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ. A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days. Cancer Chemotherapy and Pharmacology. 54: 368-76. PMID 15205914 DOI: 10.1007/s00280-004-0788-z  1
2004 Veng-Pedersen P, Chapel S, Al-Huniti NH, Schimdt RL, Sedars EM, Hohl RJ, Widness JA. Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phylebotomy-induced anemia and bone marrow ablation Biopharmaceutics and Drug Disposition. 25: 149-156. PMID 15108217 DOI: 10.1002/bdd.395  1
2003 Ownby SE, Hohl RJ. Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis. Lipids. 38: 751-9. PMID 14506838 DOI: 10.1007/s11745-003-1123-8  1
2003 Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, Widness JA. A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep Journal of Pharmacology and Experimental Therapeutics. 306: 532-537. PMID 12750427 DOI: 10.1124/jpet.103.052431  1
2003 Holstein SA, Wohlford-Lenane CL, Wiemer DF, Hohl RJ. Isoprenoid pyrophosphate analogues regulate expression of Ras-related proteins. Biochemistry. 42: 4384-91. PMID 12693933 DOI: 10.1021/bi027227m  1
2003 Holstein SA, Hohl RJ. Monoterpene regulation of Ras and Ras-related protein expression. Journal of Lipid Research. 44: 1209-15. PMID 12671036 DOI: 10.1194/jlr.M300057-JLR200  1
2003 Lee CK, de Magalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft Bone Marrow Transplantation. 31: 121-128. PMID 12621494 DOI: 10.1038/sj.bmt.1703803  1
2002 Chen X, Wiemer AJ, Hohl RJ, Wiemer DF. Stereoselective synthesis of the 5'-hydroxy-5'-phosphonate derivatives of cytidine and cytosine arabinoside. The Journal of Organic Chemistry. 67: 9331-9. PMID 12492335 DOI: 10.1021/jo020483k  1
2002 Holstein SA, Wohlford-Lenane CL, Hohl RJ. Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry. 41: 13698-704. PMID 12427032 DOI: 10.1021/bi026251x  1
2002 Lee CK, deMagalhaes-Silverman M, Hayashi M, Schlueter A, Strauss RG, Hohl RJ, Gingrich RD. A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation Bone Marrow Transplantation. 29: 647-652. PMID 12180108 DOI: 10.1038/sj.bmt.1703533  1
2002 Lee CK, de Magalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD. Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma Bone Marrow Transplantation. 29: 615-620. PMID 11979313 DOI: 10.1038/sj/bmt/1703426  1
2002 Ownby SE, Hohl RJ. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids. 37: 185-92. PMID 11908910  1
2002 Kang J, Kumar V, Yang D, Chowdhury PR, Hohl RJ. Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 15: 163-70. PMID 11849913 DOI: 10.1016/S0928-0987(01)00214-7  1
2002 Holstein SA, Wohlford-Lenane CL, Hohl RJ. Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB. The Journal of Biological Chemistry. 277: 10678-82. PMID 11788600 DOI: 10.1074/jbc.M111369200  1
2002 Chen X, Jung KY, Wiemer DF, Wiemer AJ, Hohl RJ. Phosphonate analogues of cytosine arabinoside monophosphate Phosphorus, Sulfur and Silicon and Related Elements. 177: 1783-1786. DOI: 10.1080/10426500212248  1
2001 Holstein SA, Hohl RJ. Synergistic interaction of lovastatin and paclitaxel in human cancer cells Molecular Cancer Therapeutics. 1: 141-149. PMID 12467231  1
2001 Kumar V, Kang J, Hohl RJ. Improved dissolution and cytotoxicity of camptothecin incorporated into oxidized-cellulose microspheres prepared by spray drying Pharmaceutical Development and Technology. 6: 459-467. PMID 11485187 DOI: 10.1081/PDT-100002254  1
2001 Chapel S, Veng-Pedersen P, Hohl RJ, Schmidt RL, Mcguire EM, Widness JA. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: Evidence for bone marrow as a major erythropoietin elimination pathway Journal of Pharmacology and Experimental Therapeutics. 298: 820-824. PMID 11454947  1
2001 Holstein SA, Hohl RJ. Interaction of cytosine arabinoside and lovastatin in human leukemia cells Leukemia Research. 25: 651-660. PMID 11397469 DOI: 10.1016/S0145-2126(00)00162-4  1
2001 Hohl RJ, Holstein SA. Synergy of cytosine arabinoside and lovastatin in human leukemia cells Clinical Pharmacology and Therapeutics. 69.  1
2000 Cermak DM, Wiemer DF, Lewis K, Hohl RJ. 2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization Bioorganic and Medicinal Chemistry. 8: 2729-2737. PMID 11131164 DOI: 10.1016/S0968-0896(00)00212-1  1
2000 Jung KY, Hohl RJ, Wiemer AJ, Wiemer DF. Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside. Bioorganic & Medicinal Chemistry. 8: 2501-9. PMID 11058045 DOI: 10.1016/S0968-0896(00)00183-8  1
2000 Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer. 83: 588-93. PMID 10944597 DOI: 10.1054/bjoc.2000.1316  1
2000 Lee CK, Hohl RJ, Masaki H, Schlueter A, Field E, Gingrich RD. Allogeneic hematopoietic stem cell (hsct) in patients with advanced hematological diseases using a non-myeloablative conditioning regimen Blood. 96.  1
2000 Lee CK, Hohl RJ, Schlueter A, Hayashi M, Field E, Gingrich RD. Fudarabine/cyclophosphamide followed by allogeneic peripheral blood transplantation (pbct) for older patients with advanced hematological disorders Blood. 96.  1
2000 Choon-Kee L, De Magalhaes-Silverman M, Hohl RJ, Hayashi M, Schlueter A, Gingrich RD. A phase-I, dose escalation study for salvage chemotherapy for patients with refractory lymphoma, prior to myeloablative therapy with stem cell transplantation Blood. 96.  1
1999 Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ, Lester E, Kirshner JJ, Vinciguerra V, Paskett E. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: Cancer and leukemia group B study 9473 Clinical Cancer Research. 5: 3942-3947. PMID 10632323  1
1999 Lee CK, Gingrich RD, DeMagalhaes-Silverman M, Hohl RJ, Joyce JK, Scott SD, Wen BC, Schlueter A. Prophylactic reinfusion of T cells for T cell-depleted allogeneic bone marrow transplantation Biology of Blood and Marrow Transplantation. 5: 15-27. PMID 10232737  1
1998 Hohl RJ, Sherburne AR, Feeley JE, Huisman THJ, Burns CP. Low pulse oximeter-measured hemoglobin oxygen saturations with hemoglobin Cheverly American Journal of Hematology. 59: 181-184. PMID 9798654 DOI: 10.1002/(SICI)1096-8652(199811)59:3<181::AID-AJH1>3.0.CO;2-I  1
1998 Holstein SA, Cermak DM, Wiemer DF, Lewis K, Hohl RJ. Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase Bioorganic and Medicinal Chemistry. 6: 687-694. PMID 9681134 DOI: 10.1016/S0968-0896(98)00034-0  1
1998 Hohl RJ, Lewis KA, Cermak DM, Wiemer DF. Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids Lipids. 33: 39-46. PMID 9470172 DOI: 10.1007/s11745-998-0178-x  1
1998 Gao F, Hohl RJ, Shires TK. Geranylgeraniol restores cell growth and Ras processing in mevalonate-depleted fibroblast cells Faseb Journal. 12.  1
1997 Lewis KA, Hohl RJ. Modulation of RAS expression in human malignant cells by dietary supplements Nutrition. 13: 921-923. PMID 9357036  1
1997 Hohl RJ, Pogatchnik DM, Lewis-Tibesar K, Wiemer DF. Differential inhibition of farnesyl protein transferase and squalene synthase by isoprenoid phosphonic acids Clinical Pharmacology and Therapeutics. 61: 144.  1
1996 Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer Clinical Cancer Research. 2: 483-491. PMID 9816194  1
1996 Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras Blood. 88: 4611-4619. PMID 8977253  1
1996 Peters C, Miller J, Abel SL, McMillan SK, Getchell JP, Giller RH, Hohl RJ, De Alarcon PA. Iowa newborn hemoglobinopathy screening and comprehensive care: A model for rural states [1] Journal of Pediatric Hematology/Oncology. 18: 416-418. PMID 8888756 DOI: 10.1097/00043426-199611000-00018  1
1996 Hohl RJ. Monoterpenes as regulators of malignant cell proliferation Advances in Experimental Medicine and Biology. 401: 137-146. PMID 8886132  1
1996 Lee CK, Harman GS, Hohl RJ, Gingrich RD. Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment. Bone Marrow Transplantation. 18: 573-7. PMID 8879620  1
1995 Clamon GH, Riggs CE, Dreicer R, Hohl RJ. Phase II trial of edatrexate in patients with metastatic colorectal cancer Investigational New Drugs. 13: 359-361. PMID 8824357 DOI: 10.1007/BF00873145  1
1995 Hohl RJ, Lewis K. Differential effects of monoterpenes and lovastatin on RAS processing Journal of Biological Chemistry. 270: 17508-17512. PMID 7615555 DOI: 10.1074/jbc.270.29.17508  1
1995 Lee CK, Gingrich RD, Hohl RJ, Ajram KA. Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation Bone Marrow Transplantation. 16: 175-182. PMID 7581119  1
1991 Hohl RJ, Larson RA, Mannickarottu V, Yachnin S. Inhibition of hydroxymethylglutaryl coenzyme A reductase activity induces a paradoxical increase in DNA synthesis in myeloid leukemia cells Blood. 77: 1064-1070. PMID 1995091  1
1991 Hohl RJ, Kennedy EJ, Frischer H. Defenses against oxidation in human erythrocytes: role of glutathione reductase in the activation of glucose decarboxylation by hemolytic drugs. The Journal of Laboratory and Clinical Medicine. 117: 325-31. PMID 1901343  1
1989 Hohl RJ, Schilsky RL. Nonmalignant complications of therapy for Hodgkin's disease Hematology/Oncology Clinics of North America. 3: 331-343. PMID 2663831  1
Show low-probability matches.